Universal Health Services Inc
Change company Symbol lookup
Select an option...
UHS Universal Health Services Inc
VZ Verizon Communications Inc
TSLA Tesla Inc
PFE Pfizer Inc
PYPL PayPal Holdings Inc
NFLX Netflix Inc
MSFT Microsoft Corp
MRK Merck & Co Inc
JPM JPMorgan Chase & Co

Health Care : Health Care Providers & Services | Mid Cap Blend
Company profile

Universal Health Services, Inc. is a holding company. The Company's principal business is owning and operating, through its subsidiaries, acute care hospitals and outpatient facilities, and behavioral healthcare facilities. The Company's segments include Acute Care Hospital Services, Behavioral Health Services and Other. As of August 1, 2018, the Company owned and/or operated more than 326 inpatient facilities, and 32 outpatient and other facilities, located in 37 states, Washington, District of Columbia, the United Kingdom, Puerto Rico and the United States Virgin Islands. The Company's hospitals provide a range of services, such as oncology, diagnostic care, coronary care, pediatric services, pharmacy services and/or behavioral health services. As of February 28, 2017, its acute care facilities located in the United States included 26 inpatient acute care hospitals; four free-standing emergency departments, and four outpatient surgery/cancer care centers and one surgical hospital.

Closing Price
Day's Change
-10.09 (-8.56%)
B/A Size
Day's High
Day's Low
(Heavy Day)

10-day average volume:

Roche's rheumatoid arthritis drug fails in COVID-19 trial

7:24 am ET July 29, 2020 (MarketWatch)

Shares of Roche Holding AG were up 0.4% in premarket trading on Wednesday after the drugmaker said its rheumatoid arthritis drug Actemra failed in a late-stage clinical trial as a treatment for hospitalized COVID-19 patients. The therapy did not meet the study's primary or secondary endpoints. There was no difference in the number of patients who died by week four among those taking Actemra or placebo, though the company said Actemra may speed up recovery times for hospitalized patients, a finding that needs further analysis. "We are disappointed that [the study] did not demonstrate a benefit for patients in either clinical status or mortality at week four," Dr. Levi Garraway, Roche's chief medical officer, said in a news release. The global, randomized, double-blind, placebo-controlled phase 3 trial was conducted with the Biomedical Advanced Research and Development Authority. Earlier this year there was hope that rheumatoid arthritis drugs could serve as possible treatments for COVID-19 patients; however, Regeneron Pharmaceuticals Inc.'s (REGN) and Sanofi's (SAN.FR) RA drug Kevzara also had some limitations (http://www.marketwatch.com/story/covid-19-treatment-yields-disappointing-data-in-trial-and-shows-its-not-easy-to-develop-drugs-2020-04-28) treating these patients in a recent mid-stage COVID-19 trial. Roche's stock is up 10.4% year-to-date, while the S&P 500 is down 0.3%.

-Jaimy Lee; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

July 29, 2020 07:24 ET (11:24 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.